Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alantos Pharmaceuticals
Cambridge, Massachusetts, United States
- Ownership
- Private
- Employees
- ~45
- Development stage
- Other
01
Overview
Alantos’ lead candidate was ALS 2-0426, a DPP-IV inhibitor in Phase 2a for type II diabetes. The company also had a matrix metalloproteinase inhibitor platform targeting osteoarthritis and several preclinical programs focused on inflammation and metabolic diseases. Amgen acquired the company in mid-2007 for $300 million to expand its pipeline with these assets.
- Therapeutic areas
- OncologyEndocrinologyImmunologyDermatologyRheumatologyGastroenterologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
No major disclosed partnerships
Beyond the preview
Go deeper on Alantos Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alantos Pharmaceuticals.